Biomed Valley Discoveries Phase 1/2 Trial: Ulixertinib + Ruxolitinib for Myelofibrosis
Key claim: A Phase 1/2 trial has been initiated combining ulixertinib (selective ERK1/2 inhibitor) with ruxolitinib (JAK1/2 inhibitor) as a novel dual-targeting approach for myelofibrosis.
Abstract
Biomed Valley Discoveries announced that the first patient has been dosed in a Phase 1/2 combination study of ulixertinib (a selective ERK 1/2 inhibitor) with ruxolitinib (JAK1/JAK2 inhibitor) for treatment of myelofibrosis, representing a potential novel dual-targeting treatment approach.
Why this matters
Initiation of a JAK1/2 + ERK1/2 combination trial extends the rapidly growing ruxolitinib-add-on landscape in PMF to a downstream MAPK node, addressing a recognized mechanism of JAKi escape where residual RAS/MAPK signaling sustains the malignant clone. For PMF — the highest-mortality MPN subtype with limited disease-modifying options short of allogeneic HSCT — dual JAK/ERK blockade joins parallel BET, XPO1, PI3Kδ, LSD1, and IL-1β combinations being tested for the JAKi-suboptimal subpopulation. Sponsor attribution (Biomed Valley Discoveries, the ulixertinib developer) clarifies the industry origin of an otherwise mechanism-defined entry already on the PMF page.